CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership.

Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monitoring Board) triggered the possibility for Phase 2 to begin in a larger wave of clinical trial sites in both the US and Europe.

The first patients in the MOCA II Phase II study were enrolled by Professor Marco Valgimigli at Cardiocentro Ticino Institute in Lugano, Switzerland. “I am excited to see the next generation of the CorFlow technology and advancement of the clinical program where the international pivotal study is now underway, for which the interventional cardiology community will eagerly await the results. Once the technology is readily available, it can help drive decision-making in the cath lab to improve our management of STEMI patients. Fast, accurate diagnosis of MVO is the key step we need to build from.”

CorFlow also announced that its parallel flagship clinical trial is now approved and can start enrolling patients. The novel randomized REVITALISE trial is now set to begin enrolment across UK, with France, Netherlands, and Spain following in the coming weeks. REVITALISE is intended to prospectively test the effectiveness of the proprietary CorFlow Continuous Flow Infusion System (CoFI System) to deliver therapeutic agents in treating MVO in patients undergoing primary angioplasty for acute myocardial infarction with ST segment elevation MI (STEMI). The trial intends to enroll at least 250 patients with early results expected in 2027 and data read-outs expected through 2028. The adaptive platform approach was selected due to its ability to add subsequent arms to the trial, testing the effectiveness of additional drug candidates delivered through the CorFlow system. Additional countries and research centers are also under evaluation.

Paul Mead, CEO of CorFlow, commented “With the momentum for our expanded clinical program and high interest from KOLs, we are now fortunate to be partnering with many of the top research institutions and physicians in the US and Europe to help bring the technology forward. Between both studies, we will have close to 50 top-tier hospitals engaged, each with a team motivated to see these studies succeed. Interventional cardiology, specifically in the coronary space, is at an exciting time once again with growth drivers and new options for patients. Our technology and clinical studies aim to build on that with a major step forward towards truly complete revascularization, including superior diagnosis and treatment options.”

Alongside the clinical program news, CorFlow has announced that Dr. Rick Kuntz has joined the CorFlow Board of Directors as an Observer and senior scientific advisor. Dr. Kuntz, a renowned interventional cardiologist, was a founder and Chief Scientific Officer of the Harvard Clinical Research Institute and later served at Medtronic as Chief Medical and Scientific Officer, where he oversaw medical affairs, health policy and reimbursement, clinical research activities, and corporate technology for the respected medical device leader. His experience includes guiding clinical programs for numerous technologies through market clearance and subsequent post market research for over 30 years.

CorFlow also announced the appointment of Dr. Pedro Eerdmans as Vice President Clinical. Pedro brings decades of experience from both industry, clinical research organizations, and notified bodies over his career, touching multiple medical fields. Notably, Dr. Eerdmans has helped scale medtech startups for clinical study execution, as well as spent time at larger medical companies such as Biosensors International where he served as VP Medical Affairs overseeing multiple coronary artery stent studies.

Chris O’Connell, the Chairman of the Board of CorFlow, commented, “We are thrilled with the clinical milestones that CorFlow continues to achieve, and equally excited by the added experience of our new team members. I personally had the chance to work with Dr. Kuntz at Medtronic for many years and cannot think of a better addition for CorFlow to help guide our strategic, scientific and regulatory path forward for this breakthrough technology. Our foundation will always be in medical science that puts the patient first, aiming for a new standard of care – which is possible thanks to this strengthened team and the path the company is now on with these landmark studies.”

About CorFlow Therapeutics: Founded and headquartered in Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced first announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow, starting with cardiac applications for heart attack patients. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to research applications for the unique patented technology with pharmaceutical options and new use cases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430413675/en/

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), announced that DEWA has set a new world record for the lowest electricity customer minutes lost (CML), at just 0.82 minutes (about 49 seconds) per year. With this significant achievement, DEWA has surpassed its own previous world record of 0.94 minutes in 2024, representing an improvement of around 13%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429386479/en/

Dubai records the world’s lowest electricity customer minutes lost at just 49 seconds per year (Photo: AETOSWire)

“We work in line with the vision and directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to provide the best electricity and water infrastructure in the world. We utilise the latest technologies of the Fourth Industrial Revolution, particularly artificial intelligence, which we are fully integrating into DEWA’s strategies and operations. The smart grid is a fundamental pillar of DEWA’s strategy to deliver services according to the highest standards of availability, reliability and efficiency. This supports the Dubai 2040 Urban Master Plan and the Dubai Economic Agenda (D33), which seek to consolidate Dubai’s position among the top three global cities,” said Al Tayer.

Al Tayer explained that the Smart Grid, which DEWA is implementing with total investments of AED 7 billion up to 2035, provides advanced features that enhance the efficiency of energy transmission and distribution, reduce outages, minimise losses, improve electrical load management and enhance the happiness of customers and all stakeholders. One of the key programmes is the Automatic Smart Grid Restoration System, the first of its kind in the Middle East and North Africa. The system enables remote, round-the-clock control, management and monitoring without human intervention, through innovative centralised systems that automatically locate and isolate faults and restore service, accelerating power restoration and increasing reliability.

DEWA reduced CML in Dubai from 6.88 minutes per year in 2012 to just 0.82 minutes in 2025, significantly lower than the average of approximately 15 minutes recorded by leading utility companies in the European Union. This underlines DEWA’s global leadership in adopting innovation to deliver services according to the highest reliability standards.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429386479/en/

The Internet Corporation for Assigned Names and Numbers (ICANN), the nonprofit organization that coordinates the Internet’s Domain Name System (DNS), today announced that its New gTLD Program: 2026 Round application window is now open. Generic top-level domains, or gTLDs, are the part of a web address after the last dot. For the first time in over a decade businesses, communities, governments, and other organizations have the opportunity to operate unique digital assets, such as .brand, .city, or .industry, for the use of their business, customers, or constituents.

A Strategic Tool for the Digital Era

A gTLD is a global digital identifier that can anchor businesses in the digital arena, providing control over the left and right of the dot. The previous application round in 2012 resulted in the introduction of more than 1,200 new gTLDs, including those for brands like .microsoft and .sky, geographic locations such as .africa and .berlin, and general terms like .bank and .eco. New gTLDs have demonstrated their benefits in building brand trust, creating vibrant local digital ecosystems, and providing more intuitive navigation for users.

Key Benefits of Operating a gTLD

A gTLD is a unique digital home that provides:

• Control and Flexibility: Define your own digital ecosystem by determining who can register under your domain name.
• Security: Strengthen online transactions and build robust defenses against cyber threats, protecting both your brand and your customers.
• Competitive Edge: Marketers overwhelmingly agree, with 92 percent recognizing gTLD benefits like differentiation, enhanced trust, and improved SEO.

“gTLDs are unique digital tools that can be used in meaningful and innovative ways to help achieve long-term goals,” said Kurtis Lindqvist, President and CEO, ICANN. “Whether building a brand for a company, spotlighting a geographic region or city, strengthening a community, or launching a business to offer domain names under a new registry, a new gTLD can be an innovative tool for commerce, security, and communication.”

The 2026 Round will expand the number of languages available for Internationalized Domain Names (IDNs) by accepting gTLD applications in 27 different scripts, representing hundreds of languages such as Arabic, Chinese, Devanagari, and Thai. This expansion will make the Internet more accessible and user-friendly for billions of people who use non-Latin-based scripts. 

How To Apply

The application submission window will close on 12 August 2026. Applicants must submit their applications through the online TLD Application Management System (TAMS) here.

Applicant Resources

The Applicant Guidebook is the authoritative roadmap for any entity interested in applying for a gTLD. It includes the application questions, requirements, and processes to lead applicants through the submission and evaluation processes.

Applicants are strongly advised to carefully review the TAMS resources prior to submitting an application. These resources include a system User Guide, demonstration videos, and other helpful tools, all available here. Additional resources, including Frequently Asked Questions, topic overviews, webinar recordings, and more are available on the 2026 Round Resources webpage.

Mata Sundri College for Women, University of Delhi, celebrated its 59th Annual Day on 30th April 2026 with great fervour and pride. The highlight of the evening was the gracious presence of His Excellency Ambassador Sardar Taranjit Singh Sandhu, Hon’ble Lieutenant Governor of Delhi, as the Chief Guest. The event was further elevated by the presence of Sardar Manjinder Singh Sirsa, Hon’ble Cabinet Minister, Government of NCT of Delhi, as Guest of Honour.

The programme commenced with a soulful prayer, followed by the welcome address by Prof. Harpreet Kaur, Principal, Mata Sundri College for Women. In her address, she expressed deep reverence for the Chief Guest, describing him as one who “Embodies the rare fusion of diplomatic excellence, institutional legacy, and human-centric nation-building.” She also highlighted the college’s achievements in various rankings and its rapid progress through innovative initiatives on campus.

The distinguished dais was graced by Padma Shri Sardar Vikramjit Singh Sahney, Chairman of the College Governing Body and Rajya Sabha Member; Sardar Jagdip Singh Kahlon, General Secretary, Delhi Sikh Gurdwara Management Committee (DSGMC); Professor Rawail Singh, Sardar Kulbir Singh, Shri SN Nag along with other governing body members and eminent personalities.

In his address, the Hon’ble Lieutenant Governor emphasized that “An Annual Day is an important moment in the life of an institution as it brings together achievement, reflection, and aspiration.” He lauded the college for its commitment to holistic education and women’s empowerment.

A special highlight of the evening was the live demonstration of projects developed by students under the WeSkillYou.ai “AI for Everyone skill course, running at the college.” His Excellency the Lieutenant Governor, along with Hon’ble Minister Sardar Manjinder Singh Sirsa, Padma Shri Vikramjit Singh Sahney, and other dignitaries, interacted with the students and were highly impressed by the practical, real-world AI solutions created by the young women, ranging from personal profile portal creation to a real-time sentiment analysis and comparison of any politician in the world. The dignitaries praised the initiative for bridging the gap between academic learning and industry-relevant skills.

The college magazine ‘BANI’ and the Annual Report 2025-26 were also released during the event. Several students were felicitated for academic and co-curricular excellence, with Shalini Shankar being declared “Student of the Year” and Kajal Yadav as “Best All-Rounder.”

The evening concluded with a vote of thanks by Dr. Divya Pradhan, who expressed gratitude to all dignitaries, faculty, staff, and students for making the 59th Annual Day a memorable celebration of excellence and aspiration.

For Media Queries: Public Relations Office, Mata Sundri College for Women | WeSkillYou.ai

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the Year at the Trailblazer Awards in New York City, one of the World Most Innovative Companies by Fast Company Magazine for the second time in 2025, and the winner of the World Economic Forum’s 2025 Award for Excellence in Governance and Leadership for Global Challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501700974/en/

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health.

“We are immensely honored and profoundly humbled to be named the 2026 Winner of the TIME100 Impact in Health Award and a TIME100 Most Influential Company in the World. As a mission-driven company animated by the relentless pursuit of delivering the greatest outcomes to the greatest number of patients, this recognition by TIME has only deepened our commitment to translate the promise of science into a transformative impact on the lives of our patients and their families,” said Jason Haider, Founder and CEO of Xenco Medical.

A leader in the life sciences, Xenco Medical’s breakthrough portfolio of biomimetic implants, regenerative biomaterials, composite polymer surgical systems, and its range of groundbreaking software technologies, from AI-enabled remote therapeutic monitoring to preoperative holographic surgical simulation have established it as an innovation standard-bearer. Emblematic of Xenco Medical’s mission to dissolve the barriers that typify the siloed nature of surgical care, the company’s TrabeculeX Continuum technology synergistically harmonizes the bone-forming potential of its regenerative biomaterials with AI-powered post-surgical rehabilitation. Inspired by the principles of mechanotransduction, the groundbreaking platform from Xenco Medical enables surgeons to remotely monitor pain scores, rehabilitation adherence, and motion recovery through AI-driven pose assessment over the course of the bone remodelling process.

Xenco Medical’s technologies have heralded a radically optimized, value-based approach to healthcare globally. Transforming the operational efficiency of healthcare facilities through its streamlined single-use surgical implant systems as well, Xenco Medical’s logistics-driven surgical devices have significantly decreased surgical turnover times by eliminating the need for the sterilization and reprocessing of implant and instrument systems between surgeries. A leader in its development of technologies that reverberate across the entire health ecosystem, Xenco Medical has forged a trailblazing path that has come to define the value-based era of healthcare. The Time Magazine TIME100 Most Influential Companies Edition was released on newsstands worldwide today.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260501700974/en/

In a significant step towards delivering its next landmark development, Elan Group has announced the commencement of construction of its ultra-luxury residential project, Elan The Statement, in Sector 49, Gurugram. The milestone follows the award of a Rs 840 crore contract to Tata Projects for the project’s construction, a company widely recognised for its legacy of trust and proven track record in delivering complex, large-scale projects. With a planned investment of approximately Rs 1600 crore, Elan The Statement is being developed across approximately 6 acres and further strengthens Elan Group’s growing presence in the ultra-luxury residential segment.

The development comprises 5 elegantly designed towers offering ultra-spacious residences with super area ranging from nearly 4285 sq. ft. to 7270 sq. ft. With a two-residences-per-core configuration, private lift lobbies and carefully curated interiors, each residence is designed to maximise privacy and exclusivity. Designed by Benoy from London, UK, the project’s striking metal and glass façade sets a new architectural benchmark in one of Gurugram’s most sought-after residential locations. The project’s landscape is being crafted by globally acclaimed SWA Group from California, USA, ensuring a seamless integration of nature within the development.

Mr. Rakesh Kapoor, Chairman, Elan Group, said, “Elan The Statement represents our vision of crafting future-ready developments defined by design excellence and engineering strength. The commencement of construction underscores our unwavering commitment to disciplined execution and timely delivery. With Tata Projects on board, we are confident of achieving global benchmarks across every aspect of the development. Elan The Statement will redefine new-age luxury through its architectural distinction and thoughtfully curated living experiences, rarely seen in the market. It marks a defining step in shaping the future of ultra-luxury living in India.”

Mr. Barun Pal Chowdhury, EVP and SBU Head – Buildings and Airports, Tata Projects Ltd, said, “Elan The Statement represents the next-generation of luxury developments in Gurugram, where design ambition meets execution excellence. At Tata Projects, we have consistently set benchmarks in delivering complex, large-scale infrastructure with predictability, precision and safety at the core. This project further strengthens our position as a trusted partner for marquee developments across India. Leveraging advanced engineering, robust project management frameworks and our unwavering focus on timely delivery, we are committed to creating an asset that stands out not just for its scale, but for the quality and reliability it represents.”

Elan The Statement is not just another addition to Gurugram’s ultra-luxury housing landscape but a reflection of Elan Group’s vision of creating world-class developments defined by design-led innovation, engineering precision and uncompromising quality. With an expanding portfolio of marquee projects across residential, commercial and hospitality segments, the Group continues to strengthen its position as a trusted name in India’s luxury real estate sector. The commencement of construction further reinforces Elan Group’s commitment to delivering enduring value while playing a significant role in shaping the next phase of Gurugram’s urban growth.